Effects of Dapagliflozin on Vascular Endothelial Function and Cardiac Function Indexes in Patients with Chronic Heart Failure
Objective To investigate the effects of dapagliflozin on vascular endothelial function and cardiac function indexes in patients with chronic heart failure(CHF).Methods A total of 86 CHF patients treated in Leping People's Hospital from February 2021 to February 2023 were randomly divided into two groups with 43 cases in each group according to random number table method.The control group was treated with sacubitril valsartan sodium,and the observation group was treated with sacubitril valsartan sodium combined with dapagliflozin.The duration of treatment in both groups was 2 months.The clinical effects,vascular endothelial function,cardiac function indexes,heart failure markers and adverse reactions of the two groups were compared before and after treatment.Results Compared with the control group,the total effective rate of the observation group was higher(P<0.05);the levels of FMD and NMD in observation group were higher after treatment(P<0.05);the level of left ventricular ejection fraction(LVEF)in observation group was higher,and the level of left ventricular end-diastolic diameter(LVEDD)and left ventricular end-systolic diameter(LVESD)were lower(P>0.05);the plasma levels of brain natriuretic peptide(BNP)and N-terminal brain natriuretic peptide precursor(NT-proBNP)were lower in the observation group after treatment(P<0.05).The total incidence of adverse reactions was compared between the two groups(P>0.05).Conclusion Dapagliflozin has a clear effect in the treatment of CHF patients,and can improve the vascular endothelial function of patients,regulate the level of cardiac function indicators and markers of heart failure.It is safe and worthy of promotion in clinical use.
Chronic heart failureDapagliflozinVascular endothelial functionCardiac function
NETL
NSTL
万方数据
